Evidence map›Paper›PMID 40929147›Full record

Trial reportThe journals of gerontology. Series A, Biological sciences and medical sciences2025

Effect of aspirin on grip strength and gait speed in community-dwelling older adults in the ASPirin in Reducing Events in the Elderly (ASPREE) Study.

Aung Zaw Zaw Phyo, Sara E Espinoza, Suzanne G Orchard, Rory Wolfe, Anne M Murray, Robyn L Woods, Joanne Ryan

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The journals of gerontology. Series A, Biological sciences and medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Aung Zaw Zaw PhyoSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.ORCID 0000-0002-8834-4072
Sara E EspinozaCenter for Translational Geroscience, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, United States.
Suzanne G OrchardSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Rory WolfeSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.ORCID 0000-0002-2126-1045
Anne M MurrayBerman Center for Outcomes and Clinical Research, Hennepin HealthCare Research Institute, Minneapolis, Minnesota, United States.
Robyn L WoodsSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.ORCID 0000-0003-1249-6149
Joanne RyanSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.ORCID 0000-0002-7039-6325

Funding

ASPREEMonash UniversityMonash University's Early Career Postdoctoral Fellowship ECPF24-2863229592National Health and Medical Research Council (NHMRC) of Australia 1127060National Health and Medical Research Council (NHMRC) of Australia 334047National Institute on Aging and the National Cancer Institute at the National Institutes of Health U01AG029824National Institute on Aging and the National Cancer Institute at the National Institutes of Health U19AG062682NHMRC Leadership 1 Investigato 2016438NIA NIH HHS U01 AG029824NIA NIH HHS U19 AG062682NIH HHSVictorian Cancer Agency
6 · The paper itself

Abstract

backgroundGrip strength and gait speed are key markers of physical functional capacity and general health in older people. This study aimed to examine the effect of low-dose aspirin on handgrip strength and habitual gait speed in relatively healthy older people.

methodsThe ASPREE (ASPirin in Reducing Events in the Elderly) trial randomized 19 114 community-dwelling Australians and US adults aged 70+ years (US minorities ≥65 years) who were free of overt cardiovascular disease, dementia, and limitations in activities of daily living to daily 100 mg aspirin versus placebo. Linear mixed models were used to compare the effects of treatment groups on changes in grip strength and gait speed over time, and Cox proportional hazard models were used to compare time to incident grip weakness and gait slowness between aspirin and placebo groups.

resultsOver a median of 4.7 years, the changes in grip strength (β: 0.001; 95% CI: -0.004 to 0.005) and gait speed (β: -0.004; 95% CI: -0.010 to 0.001) did not differ significantly between aspirin and placebo groups. Over the study period, 6203 participants experienced incident grip weakness, and 6947 had incident gait slowness. There was no difference in the risk of incident grip weakness (Hazard Ratio (HR): 1.05; 95% CI: 1.00, 1.10) and gait slowness (HR: 1.00; 95% CI: 0.95, 1.05) between individuals randomized to aspirin versus placebo.

conclusionsLow-dose aspirin use in relatively healthy older people did not affect gait speed or grip strength over time or reduce the risk of weakness and slowness.

Indexed as

AspirinHand StrengthWalking SpeedAgedAged, 80 and overAustraliaDouble-Blind MethodFemaleHumansIndependent LivingMaleUnited StatesAspirinAspirinClinical trialGait speedGrip strengthPhysical functional capacity

Identifiers

PMID40929147
PMCPMC12479048

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.